Business
Cannabics Pharmaceuticals Announces That Seedo is to End Pre-Sales and Commence Delivery of Its Automated Growing Devices
Cannabics Pharmaceuticals Announces That Seedo is to End Pre-Sales and Commence Delivery of Its Automated Growing Devices.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Announces That Seedo is to End Pre-Sales and Commence Delivery of Its Automated Growing Devices\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Announces That Seedo is to End Pre-Sales and Commence Delivery of Its Automated Growing Devices\nSeedo will end pre-sales on September 12th and commence delivery in the next coming weeks\nPR Newswire\nAug. 22, 2018, TEL AVIV, Israel and BETHESDA, Maryland\n\n\n\nAug. 22, 2018, TEL AVIV, Israel and BETHESDA, Maryland /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that Eroll Grow Tech Ltd (\"Seedo\"), developer of the world's first fully-automated grow device designed specifically for medical cannabis, is to end Seedo's pre-sale on September 12th at midnight EST, and commence scheduled delivery of its first units to customers in the coming weeks. \n\n\n \n \n\n \nRecently CNBX partnered with Seedo to help bring forth the company's immediate vision of supplying personalized growing units into the market, and to cooperate on enabling consistent, pesticide free, pharmaceutical-grade cannabis worldwide on a commercial scale. \n\nEyal Barad, CEO of Cannabics Pharmaceuticals, said, \"We are eager to begin empowering patients to take control over their personal medical cannabis supply, and to begin engaging into a two-way interaction with patients to share their inputs - which along with our lab's scientific data will allow us to provide current and future patients with relevant information in order to make wiser decisions concerning cannabinoid-based treatments.\"\n\n\"The commencement of device delivery marks the culmination of our combined efforts to bring together interdisciplinary knowledge to present patients with the means to ensure a safe, reliable supply of medical cannabis,\" said Seedo CEO, Zohar Levy. \"By offering remote control over the automated growing process, we are en...